To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: HIV And Cancer Patients Not Abusing THC-Derived Drug, Researchers Say URL: http://www.pslgroup.com/dg/872E6.htm Doctor's Guide June 18, 1998
CHICAGO, IL -- June 18, 1998 -- San Francisco researchers evaluating clinicians' experiences with Unimed Pharmaceuticals, Inc.'s Marinol(R) (dronabinol) found no observed cases of abuse among patients, confirming its safety in the treatment of appetite loss in people with HIV and vomiting and nausea in people with cancer. Study findings were presented today by Sarah Calhoun, president and research director, Haight Ashbury Free Clinics, Inc., San Francisco, in conjunction with the College of Problems of Drug Dependency's annual scientific meeting being held in Scottsdale, AZ. Marinol is the only legally-available synthetic form of THC, the primary psychoactive component present in Cannabis sativa L. (marijuana). The new Marinol study, which was conducted nation-wide over a nine-month period, included the collection of experiences among researchers, physicians, addiction medicine specialists and law enforcement personnel. "This study can help allay the fears of some clinicians and patients who may be worried about the dangers of using a product like Marinol," Calhoun said. "We feel this product has very low abuse potential." Among the findings: -- There is no evidence of Marinol substance abuse or diversion (transferring from legal to illegal channels) -- Marinol use remains within the therapeutic dosage range over time -- Cannabis-dependent populations have demonstrated no interest in abuse of Marinol -- Based on information gathered from law enforcement officials in major cities throughout the United States, there is no street market for Marinol and no evidence of any diversion of Marinol for sale as a street drug -- Marinol does not provide effects that are considered desirable in a drug of abuse More information on: Marinol, Unimed Pharmaceuticals, Inc. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.